XML 47 R32.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition - Narrative (Details)
$ in Millions
1 Months Ended 3 Months Ended
Dec. 31, 2021
USD ($)
Segment
Mar. 31, 2022
USD ($)
Segment
Mar. 31, 2021
USD ($)
Segment
Jan. 01, 2022
USD ($)
Disaggregation of Revenue [Line Items]        
Provisions for revenue reserves to reduce product revenues to product revenues, net   $ 63.8 $ 50.8  
Santen | Europe        
Disaggregation of Revenue [Line Items]        
Collaborative agreement, repayment of upfront payment upon termination, amount $ 8.0      
Second Santen Agreement | Santen        
Disaggregation of Revenue [Line Items]        
Upfront payment receivable       $ 88.0
Amount receivable, upon achievement of event       $ 2.0
Contingent payments receivable upon achievement of development and regulatory milestones (up to) 15.5      
Contingent payments receivable upon achievement of commercial milestones (up to) $ 60.0      
Collaborative agreement, termination by counterparty, effective after written notice period | Segment 180      
Collaborative agreement expiration, period after first commercial sale of product 3 years      
Second Santen Agreement | Santen | Expanded Territories Excluding China and India        
Disaggregation of Revenue [Line Items]        
Royalty percentage (in excess of) 25.00%      
Second Santen Agreement | Santen | China and India        
Disaggregation of Revenue [Line Items]        
Royalty percentage (in excess of) 20.00%      
Rhopressa and Rocklatan | Sales Revenue, Net | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Number of distributors | Segment   3 3  
Rhopressa and Rocklatan | Sales Revenue, Net | Customer Concentration Risk | Distributor One        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage   38.00% 36.00%  
Rhopressa and Rocklatan | Sales Revenue, Net | Customer Concentration Risk | Distributor Two        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage   35.00% 30.00%  
Rhopressa and Rocklatan | Sales Revenue, Net | Customer Concentration Risk | Distributor Three        
Disaggregation of Revenue [Line Items]        
Concentration risk percentage   26.00% 33.00%